Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Rheumatoid Arthritis (RA)~* Currently receiving a suboptimal response to a stable dose of methotrexate for treatment of Rheumatoid Arthritis (RA)~* Active Rheumatoid Arthritis (RA) at time of screening and baseline~Exclusion Criteria:~* Previous or current treatment with etanercept, other tumor necrosis factor-alpha inhibitors, or other biologic agents~* Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, at screening~* Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, within 3 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 Etanercept + methotrexate (Type: EXPERIMENTAL): Phase 1: Etanercept + methotrexate
- Phase 1 Conventional DMARD (SSZ or HCQ) + MTX (Type: ACTIVE_COMPARATOR): Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).